C‐reactive protein is an informative predictor of renal cell carcinoma‐specific mortality

C‐reactive protein (CRP) represents a promising prognostic variable in patients with sporadic renal cell carcinoma (RCC). It was hypothesized that CRP can improve the prognostic ability of standard RCC‐specific mortality (RCC‐SM) predictors in patients treated with nephrectomy for all stages of RCC.

[1]  Y. Komai,et al.  Increased preoperative serum C‐reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma , 2007, BJU international.

[2]  S. Byun,et al.  Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma , 2006, BJU international.

[3]  K. Ito,et al.  Impact of thrombocytosis and C‐reactive protein elevation on the prognosis for patients with renal cell carcinoma , 2006, International journal of urology : official journal of the Japanese Urological Association.

[4]  F. Guillé,et al.  Tumor size improves the accuracy of TNM predictions in patients with renal cancer. , 2006, European urology.

[5]  D. McMillan,et al.  The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer , 2006, British Journal of Cancer.

[6]  Douglas G Altman,et al.  Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.

[7]  S. Krüger,et al.  Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. , 2005, Kidney international.

[8]  M. Kattan,et al.  Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy , 2005, Cancer.

[9]  S. Horvath,et al.  Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. , 2004, The Journal of urology.

[10]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[11]  P. Royston,et al.  Metastatic renal carcinoma comprehensive prognostic system , 2003, British Journal of Cancer.

[12]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  K. Henry,et al.  Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. , 2002, European journal of cancer.

[14]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[15]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[16]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Mazumdar,et al.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. , 2000, Statistics in medicine.

[18]  H. Oka,et al.  Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. , 1999, The Journal of urology.

[19]  K. Fujita,et al.  Significant Prognostic Factors for 5‐Year Survival after Curative Resection of Renal Cell Carcinoma , 1998, International journal of urology : official journal of the Japanese Urological Association.

[20]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[21]  J. Blay,et al.  Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Albert,et al.  Factors influencing between-laboratory variability of C-reactive protein results as evidenced by the Belgian External Quality Assessment(EQA) Scheme. , 1994, Scandinavian journal of clinical and laboratory investigation.

[23]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.

[24]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[25]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[26]  A. Paradiso,et al.  C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. , 2005, The Journal of urology.

[27]  M. Kattan,et al.  Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. , 2004, The Journal of urology.

[28]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[29]  A. Ravaud,et al.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.

[30]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.